MX2018013565A - Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales. - Google Patents

Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales.

Info

Publication number
MX2018013565A
MX2018013565A MX2018013565A MX2018013565A MX2018013565A MX 2018013565 A MX2018013565 A MX 2018013565A MX 2018013565 A MX2018013565 A MX 2018013565A MX 2018013565 A MX2018013565 A MX 2018013565A MX 2018013565 A MX2018013565 A MX 2018013565A
Authority
MX
Mexico
Prior art keywords
cells
methods
myeloid leukemia
natural killer
acute myeloid
Prior art date
Application number
MX2018013565A
Other languages
English (en)
Inventor
Kang Lin
Voskinarian-Berse Vanessa
Herzberg Uri
Murphy Brian
Zhang Xiaokui
Hussein Mohamed
Myint Han
Wilson Keith
Nordberg Andrea
Alan Fischkoff Steven
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of MX2018013565A publication Critical patent/MX2018013565A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Abstract

En la presente se proporcionan métodos para tratar la leucemia mieloide aguda (AML, por sus siglas en inglés) y el mieloma múltiple (MM) mediante la administración de una cantidad efectiva de una población celular que comprende células asesinas naturales, en donde la población celular que comprende células asesinas naturales se produce mediante un método de tres etapas que comprende el cultivo una población de células madre o progenitoras hematopoyéticas en medios que comprenden factores de movilización de células madre, por ejemplo, métodos de tres etapas para producir células NK en medios que comprenden factores de movilización de células madre que comienzan con células madre o progenitoras hematopoyéticas de células de la placenta, por ejemplo, a partir de perfusión placentaria (por ejemplo, perfusión placentaria humana) u otros tejidos, por ejemplo, sangre del cordón umbilical o sangre periférica. Además, en la presente se proporcionan métodos para usar las células NK producidas por los métodos de tres etapas que se proporcionan en la presente para suprimir la proliferación de células de leucemia mieloide aguda. En ciertas modalidades, las células NK producidas por los métodos de tres etapas descritos en el presente documento se usan en combinación con IL-2.
MX2018013565A 2016-05-07 2017-05-05 Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales. MX2018013565A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333186P 2016-05-07 2016-05-07
US201662333187P 2016-05-07 2016-05-07
US201662415954P 2016-11-01 2016-11-01
US201662415918P 2016-11-01 2016-11-01
PCT/US2017/031255 WO2017196657A1 (en) 2016-05-07 2017-05-05 Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Publications (1)

Publication Number Publication Date
MX2018013565A true MX2018013565A (es) 2019-08-21

Family

ID=60267345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013565A MX2018013565A (es) 2016-05-07 2017-05-05 Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales.

Country Status (15)

Country Link
US (1) US11180731B2 (es)
EP (1) EP3452063A4 (es)
JP (2) JP2019519486A (es)
KR (1) KR20190005964A (es)
CN (1) CN109843304A (es)
AU (2) AU2017262581A1 (es)
BR (1) BR112018072701A2 (es)
CA (1) CA3023239A1 (es)
CO (1) CO2018012923A2 (es)
IL (1) IL262775A (es)
MX (1) MX2018013565A (es)
NZ (1) NZ747910A (es)
SG (2) SG11201809858RA (es)
WO (1) WO2017196657A1 (es)
ZA (1) ZA201807431B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276365B2 (en) * 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
US20220265712A1 (en) * 2019-06-14 2022-08-25 Celularity Inc. Populations of natural killer cells for treating cancers
CN111727961B (zh) * 2020-08-10 2020-12-01 医微细胞生物技术(广州)有限公司 一种牙髓干细胞冻存液及其冻存方法
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN114015653A (zh) * 2021-12-15 2022-02-08 山东省齐鲁干细胞工程有限公司 一种冻存脐带血来源的nk细胞及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07135969A (ja) * 1993-11-18 1995-05-30 Rikagaku Kenkyusho ナチュラルキラー細胞の前駆細胞及びその分化増殖法
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
PL2686421T3 (pl) * 2011-03-18 2021-05-31 Glycostem Therapeutics B.V. Generowanie komórek nk i progenitorów komórek nk
AU2013212457B2 (en) * 2012-01-27 2017-02-16 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
US20150010583A1 (en) 2012-02-08 2015-01-08 Ipd-Therapeutics B.V. Ex vivo nk cell differentiation from cd34+ hematopoietic cells
BR112015003149A2 (pt) * 2012-08-13 2017-08-08 Anthrogenesis Corp células natural killer e usos das mesmas.
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途

Also Published As

Publication number Publication date
JP2022095927A (ja) 2022-06-28
AU2017262581A1 (en) 2019-01-03
SG10201912837RA (en) 2020-02-27
JP2019519486A (ja) 2019-07-11
WO2017196657A1 (en) 2017-11-16
AU2022287584A1 (en) 2023-02-02
CA3023239A1 (en) 2017-11-16
BR112018072701A2 (pt) 2019-02-19
CO2018012923A2 (es) 2018-12-14
US11180731B2 (en) 2021-11-23
SG11201809858RA (en) 2018-12-28
NZ747910A (en) 2023-02-24
US20190153389A1 (en) 2019-05-23
IL262775A (en) 2018-12-31
KR20190005964A (ko) 2019-01-16
EP3452063A1 (en) 2019-03-13
EP3452063A4 (en) 2020-01-08
CN109843304A (zh) 2019-06-04
ZA201807431B (en) 2021-09-29

Similar Documents

Publication Publication Date Title
NZ747910A (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
MX2018008733A (es) Metodos para extender la capacidad replicativa de las celulas somaticas durante un proceso de cultivo ex vivo.
RU2019124982A (ru) Природные клетки-киллеры и их применение
CO2020004906A2 (es) Composiciones y métodos para la eliminación de células cd117+
WO2016135559A3 (en) Materials and methods for treatment of human genetic diseases including hemoglobinopathies
EA201791443A1 (ru) Естественные киллерные клетки и их применения
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
NZ617412A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
AU2018253575A1 (en) Natural killer cells from placenta
EP2603227A4 (en) IMPROVED HEMATOPOETIC TRIBE AND PRECURSOR CELL THERAPY
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
WO2016081032A3 (en) Mesenchymal stem cells derived from induced pluripotent stem cells
PH12020551151A1 (en) Method of producing natural killer cells and composition for treating cancer
MX2022002143A (es) Celulas inmunitarias para terapias celulares adoptivas.
ZA202004679B (en) Regeneration of genetically modified plants
JP2016506968A5 (es)
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
IL257929B1 (en) Methods for the treatment of multiple myeloma and plasma cell leukemia using T-cell therapy
MX2021003383A (es) Metodos para diferenciar celulas troncales mesenquimales.
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
MX2021013914A (es) Células, tejidos, órganos y/o animales que tienen uno o más genes modificados para supervivencia y/o tolerancia de xenoinjerto mejorada.
WO2020097568A3 (en) Oligosaccharide compositions and methods of use thereof
ZA202100888B (en) Methods of preparing personalized blood vessels